Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek email him directly: derekb.lowe@gmail.com
Twitter: Dereklowe
Since I'm on the editorial board, I should point out that the first full issue of ACS Medicinal Chemistry Letters is up, with free access for the occasion. I note with approval Dennis Liotta's lead-off editorial, which mentions that the journal will be introducing a section to highlight key patents - as far as I can tell, this is the first time a med-chem journal has explicitly acknowledged that this is where the real cutting-edge stuff often first appears in the field. (And no, I didn't have anything to do with the current batch of papers, in case anyone's wondering).
Why does the journal have only a new paper or two per week? Is that because submissions are low with the new journal? Or does it intend to have a more selective or shorter issue than, say, J Med Chem?
Organic Process R&D is another ACS journal that reports on patents, in their case it is lot easier because they are concerned mostly with process patents of the method of preparation kind, where the usefulness is relatively easy to figure out from the patent examples. I think it will be harder to separate good stuff from tailings in medchem patents because very often there is no activity data in the composition-of matter medchem patent hence it may be hard to make a comparison with other known series (unless one takes the trouble to resynthesize the compounds)
I am in full agreement with milkshake. When it comes to patents in med.chem, you have all three variations (good, bad and ugly). But, with Derek in the the front seat, am sure that one can anticipate a good direction.
Milkshake: how did your interview go? Goodluck!
looks like I will have the the job - I was told unofficially by my future bosses. Nothing in writing yet, they are creating a staff position for me - one that was not opened when I interviewed - and its a bit slow administration-wise.
Milkshake : I just stepped into my lab after posting (my blog) and then came back to see that you have responded. Further, you have job at hand! Wow! Congrats and as #5 says the best news during these unpredictable and troubling times.
=Congrats Milkshake, you have truly been a great help to me and to others as well. Thanks for your always prompt and detailed replies to my questions and your wonderful insight.
It will be intersting to see how many hot papers appear in this journal rather than J Med Chem, but I guess initialy we won't see many issues because J Med Chem only had a few (3-5) brief communications each issue. That's not going to generate many issues.
I guess longer term the journal may impact on BMCL as well, and then produce more issues (assuming there's still some med chem going on).
The patent section might be interesting but it will be a minefield trying to select out from the potential NCE filings that appear each week. And what criteria will be employed for the section? New targets? New leads? or ?
@14 - certainly a lot of authors, but not wholly impossible if it's first disclosure of everything from HTS through to clinical selection. I think you're referring to DOI:10.1021/ml900018m, so having two organizations involved certainly helps to bulk out authorship as well.
1. Anonymous on April 8, 2010 12:37 PM writes...
Why does the journal have only a new paper or two per week? Is that because submissions are low with the new journal? Or does it intend to have a more selective or shorter issue than, say, J Med Chem?
Permalink to Comment2. milkshake on April 8, 2010 1:19 PM writes...
Organic Process R&D is another ACS journal that reports on patents, in their case it is lot easier because they are concerned mostly with process patents of the method of preparation kind, where the usefulness is relatively easy to figure out from the patent examples. I think it will be harder to separate good stuff from tailings in medchem patents because very often there is no activity data in the composition-of matter medchem patent hence it may be hard to make a comparison with other known series (unless one takes the trouble to resynthesize the compounds)
Permalink to Comment3. anchor on April 8, 2010 2:10 PM writes...
I am in full agreement with milkshake. When it comes to patents in med.chem, you have all three variations (good, bad and ugly). But, with Derek in the the front seat, am sure that one can anticipate a good direction.
Permalink to CommentMilkshake: how did your interview go? Goodluck!
4. milkshake on April 8, 2010 2:17 PM writes...
looks like I will have the the job - I was told unofficially by my future bosses. Nothing in writing yet, they are creating a staff position for me - one that was not opened when I interviewed - and its a bit slow administration-wise.
Permalink to Comment5. Chemjobber on April 8, 2010 2:39 PM writes...
That's the best news I've heard all day, milkshake. Congrats.
Permalink to Comment6. Hap on April 8, 2010 2:46 PM writes...
Woo-hoo! Congratulations, Milkshake.
Permalink to Comment7. Wavefunction on April 8, 2010 2:55 PM writes...
Congrats milk!
Permalink to Comment8. anchor on April 8, 2010 3:21 PM writes...
Milkshake : I just stepped into my lab after posting (my blog) and then came back to see that you have responded. Further, you have job at hand! Wow! Congrats and as #5 says the best news during these unpredictable and troubling times.
Permalink to Comment9. mitch on April 8, 2010 6:37 PM writes...
You can see the latest articles in all of their graphical abstract splendor from here:
http://www.chemfeeds.com/acsmedchemlett.php
Mitch
Permalink to Comment10. DC on April 9, 2010 5:20 AM writes...
=Congrats Milkshake, you have truly been a great help to me and to others as well. Thanks for your always prompt and detailed replies to my questions and your wonderful insight.
Permalink to Comment11. former process chemist on April 9, 2010 7:15 AM writes...
Thanks for the tip on milkshake. He's got a great site too.
Permalink to Comment12. petros on April 9, 2010 7:37 AM writes...
It will be intersting to see how many hot papers appear in this journal rather than J Med Chem, but I guess initialy we won't see many issues because J Med Chem only had a few (3-5) brief communications each issue. That's not going to generate many issues.
I guess longer term the journal may impact on BMCL as well, and then produce more issues (assuming there's still some med chem going on).
The patent section might be interesting but it will be a minefield trying to select out from the potential NCE filings that appear each week. And what criteria will be employed for the section? New targets? New leads? or ?
Permalink to Comment13. Nick K on April 9, 2010 12:39 PM writes...
Some very nice, meaty work in the first issue, and better than a lot of the stuff in J. Med. Chem. Let's hope the journal can maintain the standard.
PS: Well done Milkshake!
Permalink to Comment14. DrSnowboard on April 12, 2010 3:22 AM writes...
Anybody else find 49 authors on a Letter a little OTT?
Permalink to Comment15. CanChem on April 12, 2010 8:31 AM writes...
@14 - certainly a lot of authors, but not wholly impossible if it's first disclosure of everything from HTS through to clinical selection. I think you're referring to DOI:10.1021/ml900018m, so having two organizations involved certainly helps to bulk out authorship as well.
Permalink to Comment